Snapshot: Nortis is a Seattle-based biotech company, founded by
former University of Washington faculty. Nortis spun-out in 2011 and is located
in the University of Washington startup incubator.
Our Mission: Nortis is dedicated to developing a new generation of in-vitro systems that advance the
discovery of novel therapies and reduce the timeline and costs associated with
their translation into the clinic.
Technology: Nortis has developed technologies for generating small
segments of human tissues and organs in microfluidic chips for the in-vitro study
of human health and disease. The technology represents an important alternative
to lab animals in pharmaceutical drug development, where more predictive
preclinical test models are urgently needed to increase clinical trial success.
This advance will overcome a large barrier to developing therapeutic drugs and
vaccines for diseases like cancer, diabetes, Alzheimer's disease, infectious
diseases, cardiovascular disease, and stroke.
Product: We are
collaborating with multiple investigators throughout the United States to
develop and validate our technology and plan to launch our first product in
is made up of seasoned medical scientists, biologists, engineers, business
experts, and consultants in regulatory affairs and intellectual property. Our
team members have significant research experience in academia and industry with
track records in inventing, developing, and marketing ground-breaking
Thomas Neumann, MD, Founder, President
founding Nortis, Dr. Neumann held leading biomedical research positions in
academia and industry. Dr. Neumann is the lead inventor of Nortis's proprietary
techniques for tissue engineering vascularized tissue/organ microenvironments.
As principle investigator of several prestigious grants from the NIH and other
organizations he has significant experience in leading multidisciplinary teams.
Alan Nelson, PhD, Co-founder and Chairman
Nelson is a serial entrepreneur who has launched several successful companies,
including NeoPath, which was acquired by Beckton Dickinson. Its FDA-approved
FocalPointTMSlide Profiler for automated analysis of PAP smears has become the
gold standard for cervical cancer screening.
David Odom, CFO
Odom has three decades of experience in starting and managing successful
national and international companies. He is an
experienced CFO and Exit Planning Consultant with a strong track record of
preparing businesses for sale and successfully transitioning ownership.